Boehringer Ingelheim China Biopharmaceuticals Site celebrates milestone to bolster Shanghai’s innovation center ambition
August 25th 2015
- The handover of Boehringer Ingelheim Biopharmaceuticals (China) Manufacturing Building marks a key milestone in Boehringer Ingelheim China Biopharmaceuticals Project.
- Operation expected to start in Q1 2017.
- contract manufacturing of biopharmaceuticals on a trial basis under the support of the government. It has been included in the 2015 Shanghai Municipal Government Work Report and the latest “22 Measures to Promote Shanghai’s Development of a Technology and Innovation Center.”
Shanghai, China, August 21, 2015 - German pharmaceutical giant Boehringer Ingelheim and Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. announced today that their jointly developed Boehringer Ingelheim Biopharmaceuticals (China) Manufacturing Building completed a successful handover. The handover of the building marks a key milestone in Boehringer Ingelheim China Biopharmaceuticals Project. It is expected to will have a significant impact on the development of Shanghai’s biopharmaceutical industry and facilitate the initiative to build Shanghai into a technology and innovation center with global influence.
“We are very pleased to hand over the manufacturing building smoothly to Boehringer Ingelheim. We believe that Boehringer Ingelheim will soon introduce its equipment, know-how, technology, and equipments, all up to international standards. It will facilitate a batch of innovation-oriented companies to industrialize their research results, and also lay a solid foundation of further development of the biopharmaceuticals industry in Shanghai and the whole country.” Lanzhong Wang, General Manager of Shanghai Zhangjiang Biotech and Pharmaceutical Base Development, said.
David Preston, Chairman and CEO of Boehringer Ingelheim China, HongKong and TaiWan, said:“Biopharmaceuticals is one of our core businesses. The facility is set to be the first and the only such site established by a leading international biopharmaceuticals manufacturer in China. Through the project, we hope to become the first global provider of biopharmaceutical contract manufacturing solutions in China, helping Chinese biopharmaceutical companies to produce and launch new biopharmaceutical products and provide Chinese patients with more high-quality and innovative bio-medicine.”
Dr. Jiali Luo, General Manager of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd., said: “The smooth handover of the biopharmaceuticals manufacturing building is a major progress in our biopharmaceuticals business in China. We expect to accelerate building the biopharmaceuticals site and start trial operation of biopharmaceutical contract manufacturing with the support of the government. We hope to break the ‘bottleneck’ in the original biopharmaceutical industry chain to turn it into a ‘service platform’. Companies specializing in pharmaceutical research can focus only on developing innovative drugs while companies specializing in pharmaceutical manufacturing can focus on commercial production process and quality control to help research-oriented companies commercialize the products and maximize their value.”
Biopharmaceutical manufacturing is one of the major industries encouraged by the 12th Five-Year-Plan both in Shanghai and at the national level. Biopharmaceutical contract manufacturing, which is a new form and model for the industry, has been included in the 2015 Shanghai Municipal Government Work Report and the latest “22 Measures to Promote Shanghai’s Development of a Technology and Innovation Center.” It is expected to facilitate implementing the innovative strategy of the biopharmaceutical industry in Shanghai.
In June 2015, Boehringer Ingelheim and the Pudong New Area Government signed the “Memorandum of Understanding on Promotion of Biopharmaceutical Manufacturing Industry.” The company plans to invest over 100 million euros in the next five years to fund the development and operations of the biopharmaceutical site in China. Currently, the workshop for pilot tests with regard to production of study samples in toxicology and early clinical supplies has been put into operation. Commercial operation is expected in the first quarter of 2017.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 146 affiliates and more than 47,700 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. Prescription Medicines, the company’s largest business segment, invested 19.9% of its sales in R&D.
Boehringer Ingelheim’s biopharmaceutical business is supported by three pillars: contract manufacturing, biosimilars and new biological entity. As one of the largest biopharmaceutical contract manufacturers, BI has successfully marketed 23 biopharmaceuticals. BI operates three development and production sites worldwide: Biberach/Riss (Germany), Vienna (Austria) and Fremont (USA) and has initiated the establishment of a new site in Shanghai (China). The company has already established a Biosimilar Business for the development of its own biosimilars. Meanwhile, BI develops manufacturing processes and analytical methods for its New Biological Entities.
About Zhangjiang Biotech & Pharmaceutical Base
Zhangjiang Biotech and Pharmaceutical Base is jointly developed by the State Ministry of Science and Technology, the Ministry of Health, the State Food and Drug Administration, Chinese Academy of Sciences and the Shanghai Municipal People's Government. It was launched in Zhangjiang in 1996, already attracting more than 500 bio-medical institutions and enterprises, covering R&D headquarters of multinational pharmaceutical companies, research institutes, large-sized pharmaceutical companies, small and medium-sized research firms, contract research organization (CRO), and public services platforms. Its main operator is Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd.
With R&D and innovation as the core driving force, the base has formed a complete industry chain with regard to new drug exploration, drug screening, pharmacological assessment, clinical research, pilot test, registration and certification, commercial production and product debut. It has become a landmark region with the most concentrated R&D facilities, strongest innovation abilities and the biggest number of new medicines in China.
National medicine evaluation data showed that the ratio of drugs that have obtained clinical approval in Zhangjiang was more than three times the national average level. The base has formed more than 230 varieties of drugs, and obtained more than 50 new drug certificates, among which 30 are first-class new drugs. Currently, more than 190 new drugs are under research and many of them will be put into commercial operation soon. More than 10 varieties are undergoing international multi-center clinical trials.
Data also showed that Zhangjiang has the largest number of cases under the National Program to Develop and Manufacture Key New Drugs, undertaking more than 150 projects currently.
More information: www.bioxcellence.com